Takaaki Mizuno, CEO of CLINIAL Inc. (Shibuya-ku, Tokyo), was invited to Presidential Symposium 6, “Should comprehensive genomic profiling be performed before first-line treatment?”, at the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO 2025), where he reported results from “A multicenter prospective study evaluating the feasibility and usefulness for treatment selection of comprehensive genomic profiling (CGP) at the time of initial treatment in patients with solid tumors (NCCH1908: UPFRONT trial).”
The NCCH1908: UPFRONT trial is a multicenter prospective study evaluating the feasibility and clinical usefulness of performing comprehensive genomic profiling (the NCC Oncopanel) before the start of first-line systemic therapy in advanced or recurrent non-small cell lung cancer, breast cancer, gastric cancer, colorectal cancer, pancreatic cancer, and biliary tract cancer. It was an investigator-initiated clinical trial conducted under the Advanced Medical Care B framework.
Based on the data obtained from the trial, the symposium primarily discussed the following:
- That performing CGP testing before first-line treatment makes it possible to identify actionable genetic alterations that could become treatment targets at an early stage
- That, as a result, treatment strategies considering options such as molecular targeted therapies and clinical trials may be examined from an earlier stage
- On the other hand, the institutional and operational challenges that stand between test results and actual treatment selection (the scope of insurance coverage, the relationship with mixed billing of insured and uninsured care, timing of testing, and so on)
In the same session, in addition to the NCCH1908: UPFRONT trial, one-year follow-up data from the Advanced Medical Care B “FIRST-Dx study” and reports on the positioning of panel testing in breast and prostate cancer were also presented, with a multifaceted discussion of the benefits and challenges of incorporating cancer gene panel testing before standard treatment.
CLINIAL will apply the knowledge gained from such investigator-initiated clinical trials and academic discussions to the development of data foundations and products that support cancer genomic medicine, contributing to a healthcare system in which more appropriate treatment options reach each individual patient.
(Reference)
Conference program: 22nd Annual Meeting of the Japanese Society of Medical Oncology, Presidential Symposium 6 “Should comprehensive genomic profiling be performed before first-line treatment?” (March 6–8, 2025, Kobe Convention Center)
https://site2.convention.co.jp/jsmo2025/program/
The usefulness and challenges of CGP testing before standard treatment: considering two trial results | Cancer information site “Oncolo”
https://oncolo.jp/news/jsmo2025_03
Under insured care it comes after the (expected) end of standard treatment — but should cancer gene panel testing be performed earlier? | Nikkei Medical
https://medical.nikkeibp.co.jp/leaf/mem/pub/search/cancer/report/202504/588191.html